VivoSeq
Infectious Disease

Cutaneous Leishmaniasis

45

Pipeline Programs↗

11

Active Trials↗

14

Companies Involved↗

Cutaneous Leishmaniasis is a moderately active landscape with 45 programs across 14 companies. The most active players are Prism Pharmaceuticals, Validus Pharmaceuticals, Bayer. 4 therapies are approved with 17 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

59/100

Pipeline Velocity

19/100

Mech. Concentration

11/100

Completion Rate

88/100

Attrition Rate

9/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

P

Prism Pharmaceuticals

1 program

Phase 2V

Validus Pharmaceuticals

1 program

Phase 2Bayer logo

Bayer

1 program

Phase 2Biogen logo

Biogen

1 program

Phase 2S

Santen Pharmaceutical Co., Ltd.

1 program

Phase 2Novartis logo

Novartis

1 program

Phase 2

Pipeline

Programs by Phase

Preclinical6

Allopurinol

Alnylam Pharmaceuticals

Meglumine Antimony

Hospital Universitário Professor Edgard Santos

Anti-Helminthic

Hospital Universitário Professor Edgard Santos

Pentostam

Sheba Medical Center

Local Application Pentostam

Tel-Aviv Sourasky Medical Center

Phase 11

Liposomal Paromomycin

Tehran University of Medical Sciences

Phase 217

Tofacitinib

Prism Pharmaceuticals

Metronidazole

DePuy Orthopaedics

Pentoxifylline

Validus Pharmaceuticals

Ciprofloxacin

Bayer

Pentavalent Antimony

Fundacion Nacional de Dermatologia

Phase 317

Imiquimod

Bausch Health Americas, Inc.

Miltefosine

Knight Therapeutics (USA) Inc

Fluconazole

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Pentamidine Isethionate

Fresenius Kabi Oncology Ltd.

Doxycycline

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved4

Levofloxacin

Wim Janssens

Gentamicin

Schering-Plough

Amphotericin B

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

Meglumine Antimoniate

University of Brasilia

Analysis

Modality Breakdown

98%

Small molecule

54 of 55 classified programs — the dominant modality here.

2%ALL OTHERSVaccine12%

Small molecule leads; the ring shows all 55 classified programs, each share of the total. Modality classified for 100% of 57 pipeline programs.

Analysis

Trial Status

68

clinical trials

Completed43 · 63%
Unknown status7 · 10%
Not yet recruiting5 · 7%
Terminated5 · 7%
Recruiting4 · 6%
Active, not recruiting2 · 3%
Other2 · 3%

Clinical Trials

Trial Activity

68 trials

Ciprofloxacin Intralesional Injection for the Treatment of Cutaneous Leishmaniasis Compared to Sodium Stibogluconate
Recruiting·—·Phase 2·NCT06798402·80 enrolled
OPTImizing MIltefosine Treatment for Cutaneous LEISHmaniasis Patients
Recruiting·IInstitute of Tropical Medicine, Belgium·N/A·NCT06514560·80 enrolled
Intralesional Injection of Levofloxacin for the Management of Cutaneous Leishmaniasis
Recruiting·—·Phase 2·NCT06797544·40 enrolled
Intralesional Injection of Metronidazole for the Management of Cutaneous Leishmaniasis
Recruiting·—·Phase 2·NCT06798415·40 enrolled
The Association of Miltefosine and Pentoxifylline to Treat Mucosal and Cutaneous Leishmaniasis: A Clinical Trial in Brazil
Active, not recruiting·UUniversity of Brasilia·Phase 2·NCT02530697·160 enrolled
Arnica Tincture Fot the Treatment of Cutaneous Leishmaniasis
Active, not recruiting·UUniversidad de Antioquia·Phase 1·NCT05094908·16 enrolled
Study Comparing Several Drugs to Understand Which Work Against Cutaneous Leishmaniasis (CL)
Not yet recruiting·IInstitute of Tropical Medicine, Belgium·Phase 3·NCT07463040·900 enrolled
A Clinical Trial to Investigate Efficacy, Safety and Pharmacokinetics (PK) of Two LXE408 Oral Regimens and Oral Miltefosine as Active Control in Participants Aged ≥ 18 Years Old With Localized Cutaneous Leishmaniasis in the Region of the Americas (AMR).
Not yet recruiting·DDrugs for Neglected Diseases·Phase 2·NCT06997159·250 enrolled
Arnica Tincture Fot the Treatment of Cutaneous Leishmaniasis II.
Not yet recruiting·UUniversidad de Antioquia·Phase 3·NCT06822478·96 enrolled
Antimicrobial Adjuvants to Revert the Imbalance of Skin Microbiota for Improved Outcomes of Complicated Cutaneous Leishmaniasis Treatment in Ethiopia
Not yet recruiting·IInstitute of Tropical Medicine, Belgium·Phase 3·NCT06695143·180 enrolled
Pilot Study: Miltefosine Gel (G-MTF) in Patients With Cutaneous Leishmaniasis
Not yet recruiting·UUniversidad Industrial de Santander·Phase 1·NCT07149753·15 enrolled
Antimony Plus Pentoxifylline in Cutaneous Leishmaniasis
Completed·PPaulo Roberto Lima Machado·Phase 2/3·NCT01381055·164 enrolled
Comparison of Standard and Alternative Antimonial Dosage in Patients With American Cutaneous Leishmaniasis
Completed·OOswaldo Cruz Foundation·Phase 2/3·NCT01301924·72 enrolled
Efficacy of Intra-lesional Injections of Glucantime Once a Week or Twice a Week in the Treatment of Anthroponotic Cutaneous Leishmaniasis (ACL)
Completed·TTehran University of Medical Sciences·Phase 3·NCT04340128
Treatment of Cutaneous Leishmaniasis With Meglumine Antimoniate Versus Meglumine Antimoniate and Allopurinol
Completed·—·N/A·NCT00480883·400 enrolled
Page 1 of 5

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)